Navigation Links
Optherion, Inc. Completes $37 Million Start Up Financing
Date:10/9/2007

alternative complement pathway -- to AMD. It was found that approximately 50% of patients with AMD suffered from variations in the CFH gene; 74% of the disease could be explained by variations in the CFH and CFB genes combined. Genetic variations on Chromosome 10 have also been implicated in AMD, and are additionally a focus of the company for therapeutic and diagnostic products.

The company's intellectual property estate is based on discoveries at the University of Iowa by Dr. Gregory Hageman and at Yale University and Rockefeller University by Dr. Josephine Hoh as well as work by investigators at other universities.

Among the sources of capital for the financing are: Quaker BioVentures, Philadelphia; Domain Associates, Princeton, NJ and San Diego; Johnson & Johnson Development Corporation, New Brunswick, NJ; Purdue Pharmaceutical Products L.P., Stamford, CT; Pappas Ventures, Research Triangle Park, NC; Biogen Idec New Ventures, Cambridge, MA, and GE Healthcare Financial Services, Chicago, IL. Colin J. Foster, Optherion's President and CEO, said: "We are gratified by the high quality of investors participating in the Series A financing. We are embarking on a program that exploits a new and exciting area of research with breakthrough potential in areas of high unmet medical need, with a primary focus on preventing blindness among those with dry AMD." Mr. Foster is the former CEO of Bayer Pharmaceuticals in the U.S. and Region Head for Bayer Pharmaceuticals in North America.

Optherion's Chief Scientific Officer is Dr. Hageman, the scientific founder of Optherion and a co-discoverer of the relationship of the genetics of CFH and CFB to AMD and MPGN-II. He is the Iowa Entrepreneurial Endowed Professor in the Department of Ophthalmology and Visual Sciences at the University of Iowa and a pioneer in the role of inflammation and the complement system in AMD. Dr. Hageman is the Principal Investigator of a recently awarded five-year, $14.6 million grant f
'/>"/>

SOURCE Optherion, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sonic Foundry completes $11.25M stock offer
2. Orion Energy completes $5M capital round
3. RedPrairie completes MARC acquisition
4. Metavante completes purchase of check processing firm
5. GE completes $1.2 billion acquisition
6. M & Is Metavante completes Brasfield Corp. acquisition
7. Metavante completes GHR Systems acquisition
8. Metavante completes TREEV acquisition
9. Johnson Controls completes sale of French unit
10. OpGen completes $5 million investment round
11. UW Hospital completes deployment of error-reducing technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 The report provides ... its definition, classification, application and industry overview. ... process, and product cost structure. Production is ... analysis also covers upstream raw materials, equipment, ... trend and proposals. In the end, the ...
(Date:12/24/2014)... Diego, CA (PRWEB) December 23, 2014 ... where their Twitter followers can submit their #HolidayInTheLab ... themselves and their lab mates. , For those struggling ... lab mates, the Pipette.com Holiday in the Lab Contest ... Pipette.com Twitter followers to send pictures of ...
(Date:12/24/2014)... December 23, 2014 PharmaBoardroom,s ... out today and available for free download , digs ... change and growth in the sector today. One ... successes has been in developing a homegrown pharmaceutical manufacturing base, ... production still remains some way off. A cursory comparison with ...
(Date:12/24/2014)... YORK , Dec. 23, 2014  NeuroLifeSciences announced ... mazindol in children with attention deficit/hyperactivity disorder published in ... . The paper, titled "Pilot Phase ... disorder" ( Konofal et al, Drug Des ... ) shows that mazindol might be an effective, ...
Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... top question of Jatropha developers is, "What impact will ... and its prominence as a viable, sustainable biofuel?" To ... January webinar has been scheduled. As a precursor to ... crucial answers to hard-hitting inquiries by Jatropha investors. ...
... SEATTLE, Jan. 14 In meetings held in association,with ... Therapeutics,Inc. (CTI) (Nasdaq and MTA: CTIC) reviewed 2009 targeted ... new drug approvals in 2009 in,addition to potential label ... venture with Spectrum Pharmaceuticals, Inc.,(Spectrum) for Zevalin. , ...
... Photonics West 2009PITTSFIELD, Mass., and BELLINGHAM, Wash., Jan. ... and photonics, and Laurin Publishing, publisher of Photonics ... the 2008 Prism Awards for Photonics Innovation, the ... Prism Awards, introduced for the first time in ...
Cached Biology Technology:Jatropha Sector Reality Check: Still Viable In Volatile Times? Upcoming Webcast Shares Latest Insights 2Jatropha Sector Reality Check: Still Viable In Volatile Times? Upcoming Webcast Shares Latest Insights 3Jatropha Sector Reality Check: Still Viable In Volatile Times? Upcoming Webcast Shares Latest Insights 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 2Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 3Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 5Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 6SPIE and Laurin Publishing Announce Prism Awards Finalists 2SPIE and Laurin Publishing Announce Prism Awards Finalists 3
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, ... fine-scale differences in genetic ancestry of individuals from across ... Since immigrants first arrived more than four hundred years ... served as a meeting place for peoples from different ... ongoing mixing of peoples with African, European, and American ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... molecular and protein signatures that predict rapid onset of ... transplant. The markers appeared soon after transplant and ... Such early detection of susceptibility to hepatitis C virus-induced ... treatment options after a transplant. Also, because the ...
... charcoal preserved in deeply buried sediments in Egypt,s Nile ... a huge drought 4,200 years ago associated with the ... the pyramid-building time. "Humans have a long history ... Bernhardt, a researcher with the U.S. Geological Survey. "Along ...
... NC Leukemia and lymphoma patients who receive life-saving ... side effects that significantly decrease quality of life, can ... In chronic Graft vs. Host Disease ... and the recipient,s body often cause these immune cells ...
Cached Biology News:Molecular and protein markers discovered for liver transplant failure from hepatitis C 2Molecular and protein markers discovered for liver transplant failure from hepatitis C 3Molecular and protein markers discovered for liver transplant failure from hepatitis C 4Climate and drought lessons from ancient Egypt 2B cell survival holds key to chronic graft vs. host disease 2
... uses the Adept CE 4100 high pressure dual ... detector for added flexibility and utra low drift. ... to a photodiode array detection and provides superior ... required for method development and for monitoring to ...
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z71,448-8) or contact ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (E6027) or contact customer s...
Biology Products: